ng thi, sn phm cng h tr ci thin tnh trng mt cn bng ni tit t n, ci thin sc khng v th cht mt cch ng k
Agenda Co-chairs Dr Luz de Regil Director, Department of Nutrition and Food Safety, WHO and Dr Kirsten Bibbins Domingo Editor-in-Chief, JAMA Moderator Dr Gaya Manori Gamhewage, Director, Department of Communication, WHO Welcoming Dr Luz De Regil Director NFS, WHO and Dr Kirsten Bibbins-Domingo, Editor-in-Chief, JAMA Presentation: WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults Dr Francesca Celletti, Senior Advisor Obesity, Department of Nutrition and Food Safety, WHO and Dr
There is a potential for side effects, however, they are only mild to moderate
Patientreported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, openlabel study